600511 国药股份
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入38,028,5404.10%49,696,04645,498,58446,468,60340,378,608
减:营业总成本36,311,0694.33%47,194,08943,218,51344,351,26738,790,277
    其中:营业成本35,359,7574.92%45,704,77641,676,31842,837,50037,235,801
               财务费用(73,667)218.13%(126,127)(28,840)(18,342)(6,810)
               资产减值损失(6,831)-68.32%389(5,140)(17,588)(6,479)
公允价值变动收益----10,817------
投资收益316,41410.26%358,952291,622283,351220,599
    其中:对联营企业和合营企业的投资收益320,213-2.73%456,539380,800380,222327,623
营业利润1,989,261-0.23%2,944,3582,694,9232,447,2741,913,218
利润总额1,965,834-1.02%2,930,8902,687,8862,444,8061,917,346
减:所得税费用390,907-3.28%596,420559,181516,303408,095
净利润1,574,927-0.44%2,334,4712,128,7051,928,5031,509,251
减:非控股权益93,655-21.70%188,472164,648174,418126,562
股东净利润1,481,2721.30%2,145,9991,964,0581,754,0841,382,688

市场价值指针
每股收益 (元) *1.9631.30%2.8442.6032.3251.833
每股派息 (元) *----0.8540.7820.7000.550
每股净资产 (元) *22.01210.08%20.90918.84016.93815.167
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容